EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy

Jing-Fu Bao, Bao-Cheng Guo, Jia-Ju Mo, Hongguo Zhu, Nan Jia, Fanfan Hou, Youhua Liu, Aiqing Li iD

Disease Models & Mechanisms · 2026

DOI: 10.1242/dmm.052395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2026. Verfasst von Jing-Fu Bao und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, …. Hauptthemen laut MEDLINE: Cardiomyopathies, Uremia, Receptors, CCR2. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangdong Provincial Clinical Research Center for Kidney Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uremic cardiomyopathy (UC) represents a leading cause of mortality in patients with chronic kidney disease (CKD), characterized by left ventricular hypertrophy (LVH) and fibrosis. The underlying mechanisms of UC pathogenesis remain incompletely understood. This study developed two methods to simulate human UC – modified nephrectomy (MNx) and adenine-normal combinational diet – and compared these approaches across several rodent strains. Transcriptomic analysis was performed on left ventricular tissues from these models. The analysis revealed global changes in UC, including dysregulated cell cycle processes, enhanced extracellular matrix remodeling and metabolic abnormalities, while also highlighting molecular distinctions between MNx- and adenine-induced UC. Notably, this study identified C-C-motif receptor 2 (CCR-2) as a novel potential antifibrotic target in UC. CCR-2 blockade substantially reversed fibrosis without affecting LVH. The mechanism through which CCR-2 inhibition suppresses cardiac fibrosis development in UC appears to involve the promotion of cardiac residual macrophage expansion. These findings establish a central role for CCR-2 in cardiac fibrosis and suggest CCR-2 inhibition as a promising therapeutic target for UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesUremiaReceptors, CCR2AnimalsFibrosisHumansMyocardiumMaleMacrophagesDisease Models, AnimalMice, Inbred C57BLExtracellular Matrix

Stichwörter der Autor:innen

C-C chemokine receptor 2FibrosisRodent modelTranscriptomeUremic cardiomyopathy

Substanzen

Receptors, CCR2

Autor:innen und Institutionen

  • State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, China.
  • Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangdong Provincial Clinical Research Center for Kidney Disease, 510005 Guangzhou, China.
  • Department of Nephrology, The Fourth Affiliated Hospital of Guangzhou Medical University, 511300 Guangzhou, China.

ORCID-Profile: Aiqing Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Guangdong Provincial Clinical Research Center for Kidney Disease
  • China Postdoctoral Science Foundation
  • Southern Medical University

Zitieren

APA

Bao, J. F., Guo, B. C., Mo, J. J., Zhu, H., Jia, N., Hou, F., Liu, Y., & Li, A. (2026). C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052395

Vancouver

Bao JF, Guo BC, Mo JJ, Zhu H, Jia N, Hou F, et al. C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy. Disease Models & Mechanisms. 2026. doi:10.1242/dmm.052395

BibTeX
@article{Bao2026,
  author = {Bao, Jing-Fu and Guo, Bao-Cheng and Mo, Jia-Ju and Zhu, Hongguo and Jia, Nan and Hou, Fanfan and Liu, Youhua and Li, Aiqing},
  title = {C-C motif receptor 2 is a core profibrotic factor in uremic cardiomyopathy},
  journal = {Disease Models & Mechanisms},
  year = {2026},
  doi = {10.1242/dmm.052395}
}
Kostenlos starten →